title: [Measurement of bronchoconstrictive eicosanoids in chronic obstructive pulmonary disease].
abstract: BACKGROUND
  The aim of the study was the evaluation of the concentration of 9α11β prostaglandin F(2) - a stable metabolite of prostaglandin D(2) (PGD(2)) and leukotriene E(4) (LTE(4)) in stable and exacerbated COPD patients.
  
  
  METHODS
  29 COPD patients aged 73 ± 8.34, mean FEV1 = 48.64 ± 15.75% of predictive value and 29 healthy controls aged 57.48 ± 10.86, mean FEV1 = 97.17 ± 13.81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease; LTE(4) was determined in urine using commercial enzyme immunoassay (EIA) and 9α11β prostaglandin F(2) (9α11βPGF(2)) - stable metabolite of PGD(2) was evaluated in blood and urine using GC/MS.
  
  
  RESULTS
  LTE(4) concentration in urine (677.15 vs. 436.4 pg/mg of creatinine; p = 0.035) and 9α11βPGF(2) in blood serum (5.35 vs. 3.07 pg/ml; p = 0.007) were significantly higher in exacerbated COPD patients than in control group. There was no difference in LTE(4) level in urine and 9α11βPGF2 in blood serum between exacerbated and stable COPD. The urinary 9α11βPGF(2) concentration did not differ between all studied groups. We found a positive correlation between smoking history and the urine LTE(4) level (r = 0.395; p = 0.002) as well as blood 9α11βPGF(2) concentration (r = 0.603; p = 0.001) in COPD patients.
  
  
  CONCLUSIONS
  9α11βPGF(2) and LTE(4) level in urine did not differ between the stable COPD group and the control group. We also did not find any difference between LTE4 level in urine and 9α11βPGF(2) in blood and urine between exacerbated and stable COPD. Finally, LTE(4) concentration in urine and 9α11βPGF(2) in blood occurred to be significantly higher in exacerbated COPD patients than in control group.
authors.affiliation: Oddział Kliniczny Kliniki Pulmonologii Szpitala Uniwersyteckiego w Krakowie, ul. Skawińska 8, Kraków. iwong@poczta.onet.pl
authors.forename: Iwona
authors.initials: I
authors.lastname: Gross-Sondej
authors.forename: Jerzy
authors.initials: J
authors.lastname: Soja
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Sładek
authors.forename: Grażyna
authors.initials: G
authors.lastname: Pulka
authors.forename: Wojciech
authors.initials: W
authors.lastname: Skucha
authors.forename: Ewa
authors.initials: E
authors.lastname: Niżankowska-Mogilnicka
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D016084:Bronchoconstriction / Q000502:physiology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D017999:Leukotriene E4 / Q000097:blood* / Q000652:urine*; D008297:Male; D008875:Middle Aged; D015230:Prostaglandin D2 / Q000097:blood* / Q000652:urine*; D029424:Pulmonary Disease, Chronic Obstructive / Q000378:metabolism*; D012016:Reference Values; D015203:Reproducibility of Results; D012129:Respiratory Function Tests; D012307:Risk Factors; D012720:Severity of Illness Index; D014797:Vital Capacity
chemical_list: D017999:Leukotriene E4; D015230:Prostaglandin D2